HIV/AIDS Therapy
Reports outline HIV/AIDS therapy study results from University of Barcelona
Published in AIDS Weekly, April 19th, 2010
A report, 'Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study,' is newly published data in Journal of Acquired Immune Deficiency Syndromes. "Raltegravir in combination therapy has demonstrated potent suppression of HIV-1 with a favorable safety profile. This report provides 96-week efficacy and safety data from Protocol 005, a Phase II study," scientists in Barcelona, Spain report.
"HIV-infected patients with very limited treatment options and failing antiretroviral therapy were randomized to raltegravir 200, 400, or 600 mg or placebo b.i.d., plus optimized background therapy for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2010-04-19)
More Articles from AIDS Weekly
- Duke University Medical Center
Scientists identify how a novel class of antibodies inhibits HIV infection - Elsevier Health Sciences
New investigation supports correlation between XMRV and prostate cancer - Antiretrovirals
Researchers from University of California publish new studies and findings in the area of antiretrovirals - Cancer Gene Therapy
Research from National Cancer Institute provide new insights into cancer gene therapy - Disease Progression
Studies from University of Glasgow add new findings in the area of disease progression - Hepatitis B Virus
Researchers from University of Pittsburgh report on findings in hepatitis B virus - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
